What is the difference between dextroamphetamine and amphetamine salts in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) or narcolepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dextroamphetamine vs Amphetamine Salts: Key Differences

Dextroamphetamine and mixed amphetamine salts (Adderall) are both highly effective first-line treatments for ADHD and narcolepsy with comparable efficacy, but mixed amphetamine salts may offer superior retention in treatment. 1

Composition and Formulation

  • Dextroamphetamine is a single-isomer formulation containing only the dextro (right-handed) enantiomer of amphetamine 2, 3

  • Mixed amphetamine salts (Adderall) contain a 3:1 ratio of dextroamphetamine to levoamphetamine, specifically: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate 4

  • Both medications are DEA Schedule II controlled substances with high potential for abuse 5

Clinical Efficacy

  • A Cochrane systematic review found that all three amphetamine derivatives (dextroamphetamine, lisdexamfetamine, and mixed amphetamine salts) significantly improved ADHD symptom severity with a standardized mean difference of -0.72 (95% CI -0.87 to -0.57) 1

  • Mixed amphetamine salts demonstrated a unique advantage in increasing retention in treatment compared to dextroamphetamine alone, though the mechanism for this difference is unclear 1

  • In adults with ADHD, mixed amphetamine salts at an average dose of 54 mg daily (administered in two divided doses) produced a 42% decrease in ADHD Rating Scale scores (P<0.001), with 70% of subjects achieving clinically meaningful improvement (≥30% reduction) versus 7% with placebo 4

  • For narcolepsy, dextroamphetamine 30 mg daily was only slightly more potent than 10 mg daily in reducing attack frequency, with both doses roughly halving the reported frequency of narcoleptic attacks 6

Dosing Considerations

For ADHD:

  • Dextroamphetamine: Start with 5 mg once or twice daily in patients ≥6 years; titrate by 5 mg weekly intervals until optimal response; rarely necessary to exceed 40 mg/day total 2

  • Mixed amphetamine salts: Start with 10 mg once daily in the morning for adults; titrate by 5 mg weekly based on response and tolerability; maximum recommended daily dose is 50 mg for adults 7

For Narcolepsy:

  • Both medications: Usual dose range is 5-60 mg per day in divided doses 2
  • For patients aged 6-12 years: Start with 5 mg daily; increase by 5 mg weekly 2
  • For patients ≥12 years: Start with 10 mg daily; increase by 10 mg weekly 2

Pharmacokinetic Profiles

  • Immediate-release formulations of both medications provide 4-6 hours of clinical action, requiring multiple daily doses (typically given on awakening with additional doses at 4-6 hour intervals) 8, 2

  • Extended-release mixed amphetamine salts (Adderall XR) provide approximately 8-9 hours of symptom control 9

  • Dextroamphetamine extended-release (Dexedrine Spansules) similarly provides 8-9 hours of coverage 9

  • Most patients could not distinguish subjective effects between immediate-release dextroamphetamine tablets and extended-release Spansules 6

Side Effect Profile

  • Both medications share similar sympathomimetic side effects including hyperactivity, hyperthermia, tachycardia, tachypnea, mydriasis, tremors, and potential seizures in overdose 5

  • Appetite suppression is more commonly reported with mixed amphetamine salts compared to other ADHD medications 10

  • Amphetamines as a class were associated with significantly higher dropout rates due to adverse events (RR 3.03; 95% CI 1.52 to 6.05) compared to placebo 1

  • Cardiovascular monitoring (blood pressure and pulse) is required at baseline and regularly during treatment with both medications 10, 7

Clinical Decision-Making Algorithm

When choosing between these medications:

  1. Start with mixed amphetamine salts (Adderall) if treatment retention is a concern, as this formulation has demonstrated superior adherence in clinical trials 1

  2. Consider dextroamphetamine if the patient has previously responded well to single-isomer formulations or if cost is a significant barrier (generic dextroamphetamine may be less expensive) 2

  3. Use extended-release formulations (Adderall XR or Dexedrine Spansules) for once-daily dosing to improve adherence and reduce stigma associated with in-school dosing 10, 9

  4. If inadequate response occurs after adequate treatment with one amphetamine formulation, approximately 40% of patients respond to both methylphenidate and amphetamines, while 40% respond to only one class—trial the other stimulant class (methylphenidate) before abandoning stimulants entirely 10

Common Pitfalls to Avoid

  • Do not assume higher doses are always better: More than 70% of patients respond when a full range of doses is properly titrated, but excessive dosing can paradoxically worsen attention and cause overstimulation 7

  • Avoid late evening doses of either medication due to resulting insomnia 2

  • Do not use with MAO inhibitors due to risk of severe hypertension and potential cerebrovascular accidents; allow at least 14 days between discontinuation of an MAOI and initiation of amphetamines 10

  • Exercise caution in patients with substance abuse disorders: Consider long-acting formulations with lower abuse potential or non-stimulant alternatives like atomoxetine 10

References

Research

Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults.

The Cochrane database of systematic reviews, 2011

Research

Adderall® (amphetamine-dextroamphetamine) toxicity.

Topics in companion animal medicine, 2013

Research

Amphetamine, mazindol, and fencamfamin in narcolepsy.

British medical journal (Clinical research ed.), 1985

Guideline

Dose Considerations and Monitoring for Adults with ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Methylphenidate Extended-Release Formulations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Medication Options for Managing Both Mood Symptoms and ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the proper usage and dosage guidelines for Adderall (amphetamine and dextroamphetamine)?
What are the considerations for adding Adderall (amphetamine and dextroamphetamine) 30 mg twice a day to a Dyanavel XR (amphetamine) dose?
What is the recommended treatment plan for a patient with Attention Deficit Hyperactivity Disorder (ADHD), specifically considering Adderall (dextroamphetamine and amphetamine) as a potential medication option?
Is it safe to take 90 mg of Adderall (amphetamine and dextroamphetamine)?
What is the equivalent dosing of Dexedrin (Dextroamphetamine) IR for a patient converting from Adderall (Amphetamine) 30 mg Immediate Release (IR) twice a day (BID)?
Is Aztreonam (monobactam antibiotic) + Vancomycin (generic name) an appropriate initial antibiotic regimen for a patient with possible acute bacterial meningitis?
What is the best course of treatment for a patient with a partial thickness burn to the chest?
What treatment adjustments can be made for a patient in their 30s with insomnia, Attention Deficit Hyperactivity Disorder (ADHD), prior methamphetamine (meth) abuse, and Obsessive-Compulsive Disorder (OCD) traits, currently taking Intuniv (guanfacine) 2mg, Doxepin 3mg, and Mirtazapine 15mg, who is experiencing persistent sleep disturbances?
Can Ribociclib (a cyclin-dependent kinase 4/6 inhibitor) cause transaminitis (elevations in liver enzymes such as alanine transaminase (ALT) and aspartate transaminase (AST)) in patients, particularly those with pre-existing liver conditions?
What is the most appropriate initial investigation for a patient complaining of daytime sleepiness, nocturia, orthopnea, with bilateral lower limb (BL LL) edema, high blood pressure (hypertension), and low oxygen saturation (hypoxemia), and a clear chest?
At what age should colon cancer screening be stopped in an older adult patient with a significant smoking history and average risk of colon cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.